Preview: ADCs & beyond

Antibody-drug conjugates and targeted radiopharmaceuticals promised chemotherapies and radiotherapies with fewer side effects by delivering cytotoxic cargos more specifically to the site of action, usually in tumours. However, despite approved drugs, there is still a great need for optimisation in terms of tumour selectivity, linker stability, stoichiometric drug-to-antibody ratio, payload or even the generation and expression of tumour-specific antibody-like targeting molecules. This special feature presents the latest developments in a market that is opening up major growth opportunities for service providers in particular.